Tags

Type your tag names separated by a space and hit enter

Cisapride versus ranitidine in the treatment of reflux esophagitis.
Hepatogastroenterology. 1988 Jun; 35(3):125-7.H

Abstract

The healing effect of the prokinetic drug cisapride (10 mg q.i.d.) on esophageal lesions, and its therapeutic control of gastroesophageal reflux symptoms were compared with the effects of the H2-antagonist ranitidine (150 mg b.i.d. + placebo b.i.d.) in a double-blind trial. In each group, 28 patients with Savary-Miller Grade I or II esophagitis were treated for 6 or 12 weeks. At the end of treatment, follow-up endoscopy showed that mucosal lesions were absent in 89% of the cisapride patients and in 79% of the ranitidine patients. In addition, 86% and 82% of the patients in the cisapride and the ranitidine group, respectively, had no, or only mild, reflux symptoms. Minor side effects were experienced in both groups. From these data, cisapride appears to be as effective as ranitidine in controlling reflux symptoms and in promoting the healing of mucosal lesions in milder forms of reflux esophagitis.

Authors+Show Affiliations

Department of Gastroenterology, University Hospital Charlottenburg, Berlin, FRG.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

3042576

Citation

Janisch, H D., et al. "Cisapride Versus Ranitidine in the Treatment of Reflux Esophagitis." Hepato-gastroenterology, vol. 35, no. 3, 1988, pp. 125-7.
Janisch HD, Hüttemann W, Bouzo MH. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology. 1988;35(3):125-7.
Janisch, H. D., Hüttemann, W., & Bouzo, M. H. (1988). Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepato-gastroenterology, 35(3), 125-7.
Janisch HD, Hüttemann W, Bouzo MH. Cisapride Versus Ranitidine in the Treatment of Reflux Esophagitis. Hepatogastroenterology. 1988;35(3):125-7. PubMed PMID: 3042576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cisapride versus ranitidine in the treatment of reflux esophagitis. AU - Janisch,H D, AU - Hüttemann,W, AU - Bouzo,M H, PY - 1988/6/1/pubmed PY - 1988/6/1/medline PY - 1988/6/1/entrez SP - 125 EP - 7 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 35 IS - 3 N2 - The healing effect of the prokinetic drug cisapride (10 mg q.i.d.) on esophageal lesions, and its therapeutic control of gastroesophageal reflux symptoms were compared with the effects of the H2-antagonist ranitidine (150 mg b.i.d. + placebo b.i.d.) in a double-blind trial. In each group, 28 patients with Savary-Miller Grade I or II esophagitis were treated for 6 or 12 weeks. At the end of treatment, follow-up endoscopy showed that mucosal lesions were absent in 89% of the cisapride patients and in 79% of the ranitidine patients. In addition, 86% and 82% of the patients in the cisapride and the ranitidine group, respectively, had no, or only mild, reflux symptoms. Minor side effects were experienced in both groups. From these data, cisapride appears to be as effective as ranitidine in controlling reflux symptoms and in promoting the healing of mucosal lesions in milder forms of reflux esophagitis. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/3042576/Cisapride_versus_ranitidine_in_the_treatment_of_reflux_esophagitis_ DB - PRIME DP - Unbound Medicine ER -